AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US 8h
DATROWAY® granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy 03 February
